- $1.87m
- -$1.27m
- $2.49m
GeoVax Labs Inc expected to post a loss of $2.88 a share - Earnings Preview
NASDAQ RESUMED AT 10:08 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:03 AM
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: GeoVax Labs Announces $2.5 Million Registered Direct Offering
Brief: Geovax Labs To Initiate Phase 3 Trial In second half of 2026
Brief: GeoVax Labs Got Written Notification From Advanced Technology International
GeoVax tumbles as HHS ends mid-stage COVID vaccine trial
GeoVax Labs Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: GeoVax Labs Inc - Enters Placement Agency And Securities Purchase Agreements With A.G.P./Alliance Global Partners - SEC Filing
GeoVax Labs Inc expected to post a loss of 77 cents a share - Earnings Preview
GeoVax Labs Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Geovax Announces Positive Interim Data Review For Phase 2 Clinical Trial Of Covid-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia
GeoVax Labs Inc reports results for the quarter ended September 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Home Depot, Live Nation, On Holding